| Literature DB >> 19369036 |
Julio Echegoyen1, Caren Armstrong, Robert J Morgan, Ivan Soltesz.
Abstract
Effective prophylaxis for post-traumatic epilepsy currently does not exist, and clinical trials using anticonvulsant drugs have yielded no long-term antiepileptogenic effects. We report that a single, rapid post-traumatic application of the proconvulsant cannabinoid type-1 (CB1) receptor antagonist SR141716A (Rimonabant-Acomplia) abolishes the long-term increase in seizure susceptibility caused by head injury in rats. These results indicate that, paradoxically, a seizure-enhancing drug may disrupt the epileptogenic process if applied within a short therapeutic time window.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19369036 PMCID: PMC2767525 DOI: 10.1016/j.eplepsyres.2009.02.019
Source DB: PubMed Journal: Epilepsy Res ISSN: 0920-1211 Impact factor: 3.045